OBJECTIVES : To create an evidence map of cost and resource use studies of patients with acute myeloid leukaemia, the geographical settings in which these studies were conducted, and the interventions assessed.

METHODS : We searched the heoro.com database (www.heoro.com) for cost and resource use studies in acute myeloid leukaemia published between 1960 and 5^th December 2017, and analysed the abstracts identified by the search to determine the types of direct and indirect cost and resource use cited across the range of geographical locations and interventions. We presented the results as an evidence map.

RESULTS : We found a total of 78 abstracts that reported costs and resource across 19 countries. Of these abstracts, 61 reported direct costs, 13 reported indirect costs, 23 reported resource use and 5 are unclear. A total of 59 different interventions were identified with unspecified chemotherapy as the most popular intervention, cited in 15 abstracts, followed by posaconazole (9), G-CSF (9) and bone marrow transplants (9). The USA was the most frequent location for the studies, with 20 abstracts, followed by the Netherlands (8), the UK (7) Canada (6) and France (6). The studies most frequently recruited general members of the acute myeloid leukaemia population with no specified age group (49), but 10 abstracts cited adults specifically, 11 assessed elderly patients, 5 evaluated children and 6 did not specify their population.

CONCLUSIONS : Economic burden studies in acute myeloid leukaemia have most commonly explored the direct costs associated with chemotherapy and interventions to prevent adverse events associated with chemotherapy. A minority of studies reported indirect costs or explored the economic burden specifically in children.